Alaunos Therapeutics, Inc. (TCRT)

From the record

Alaunos Therapeutics, Inc.'s filings since 2017 show 13 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 11 times, the latest 2026-10-21); an auditor change (8-K item 4.01, the latest 2024-06-21); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2021-08-09) (its current reports).

From the record

Alaunos Therapeutics, Inc.'s 9 filed years say what it did: revenue went from $7 million in fiscal 2016 to $5 thousand in fiscal 2025, down 55.2% a year; it rose in 2 of 7 years; the deepest fall was 100% from fiscal 2016 to fiscal 2020; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Alaunos Therapeutics, Inc. lost about 194 cents for every dollar of shareholders' money. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 21.7% over the year (the filed statements).

From the record

Alaunos Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $5 thousand in fiscal 2025 ranks in the bottom 1% by size; a net margin of -83520% ranks in the bottom 3%; revenue growth of -88% a year over the last 3 filed years ranks in the bottom 1% (its annual reports).

From the record

Alaunos Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Weis, Holger (CEO, as filed), filing under that title since 2025-07-07, 1.4 years (bottom 18% of its family); the 5 officers and directors filing in the last fifteen months have been on the record a median of 5.7 years (top 48%); 12 officer or director changes were reported on Form 8-K since 2023-11-13, against the 5 people in charge now (bottom 2%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Alaunos Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $1 million against no long-term debt tagged leaves 46.7% of its assets as net cash, top 34% of its family; cash from operations less capital spending is -59340% of revenue (bottom 3%); research spending of 27260% of revenue (top 3%) (its annual report).

From the record

Alaunos Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -88% a year over the last three filed years against -55.2% over all 9, slowing (bottom 17% of its family); the newest year grew -50% (bottom 16%); research spending grew -62.1% a year (bottom 3%); capital spending grew -23.2% a year (bottom 41%) (its annual reports). Alaunos Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Alaunos Therapeutics, Inc.'s newest year against its own record: revenue of $5 thousand in fiscal 2025 came in 753% above the $1 thousand its prior three years' pace pointed to (top 7% of its family); net income of $4 million against a prior three-year average of $16 million (top 23%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 2%) (its annual reports).